AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
49 hedge funds and large institutions have $2.87M invested in AEON Biopharma Inc in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 10 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
8% less funds holding
Funds holding: 53 → 49 (-4)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
49% less capital invested
Capital invested by funds: $5.62M → $2.87M (-$2.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$17.3K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.76K |
| 3 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
+$3.74K |
| 4 |
SG
StoneX Group
New York
|
+$2.92K |
| 5 |
Jane Street
New York
|
+$2.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
-$4K |
| 2 |
RA
Ramius Advisors
New York
|
-$3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.7K |
| 4 |
FIG
Fortress Investment Group
New York
|
-$2.1K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2K |
AEON.WS Hedge Fund Activity: Q1 2023 in Review
49 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q1 2023, worth a combined $2.87M — down 49% from $5.62M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AEON.WS and 7 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 7 added.
The largest buyer was Shaolin Capital Management, adding an estimated $17.3K. The largest seller was HGC Investment Management, exiting entirely with an estimated $4K sold.
- 49 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q1 2023, down from 53 in Q4 2022.
- Funds reported $2.87M of AEON Biopharma Inc stock for Q1 2023, down 49% quarter-over-quarter.
- 7 funds opened new AEON Biopharma Inc positions in Q1 2023 and 10 closed out, a net change of -3 holders.
- The largest AEON Biopharma Inc buyer in Q1 2023 was Shaolin Capital Management, an estimated $17.3K added.
- The largest AEON Biopharma Inc seller in Q1 2023 was HGC Investment Management, an estimated $4K sold.
Based on aggregated 13F filings for Q1 2023.